ArticleFrontiers in cardiovascular medicine2025
Cardiac Contractility Modulation as bridge to recovery in a patient with advanced heart failure evaluated for left ventricular assist devices: a case report and review of literature.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report illustrates the effects of CCM as a bridge to recovery in a patient who has been a candidate for LVAD. After CCM the patient hase become stable in NYHA class II, with no further acute HF episodes and a significant clinical and functional improvements. Consequently, the patient was no longer an LVAD candidate, as CCM had acted as a bridge to recovery, making the advanced HF designation no longer applicable. The ease of implantation, uneventful procedural recovery, extraordinary device longevity, and favorable risk profile all position CCM as an important tool in the treatment of advanced HFrEF patients candidate to LVAD therapy, serving as a bridge to recovery.Further large-scale randomized controlled trials are needed to confirm the long-term benefits of CCM therapy in this particular population subgroup, helping a better patient selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.